No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant Chemotherapy

NEO-NAUTILUS is a prospective, multicenter, randomized phase III clinical trial to evaluate whether omitting axillary lymph node surgery (ALND or SLNB) in clinically lymph node-negative breast cancer patients after neoadjuvant chemotherapy is non-inferior to performing SLNB in terms of 5-year disease-free survival.

Trial Details

NCT ID
NCT06704945
Phase
PHASE3
Sponsor
Seoul National University Hospital
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • No axillary surgery
  • Axillary surgery
Locations (sample)
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Women aged ≥19 years.
  • Histologically confirmed invasive breast carcinoma treated with neoadjuvant chemotherapy.
  • Clinical staging prior to NAC: cT1-3, cN0, M0 (AJCC 8th Edition).
  • If pre-NAC staging is cT1-3, cN1, M0, must meet the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →